PH12020551185A1 - Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation - Google Patents

Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Info

Publication number
PH12020551185A1
PH12020551185A1 PH12020551185A PH12020551185A PH12020551185A1 PH 12020551185 A1 PH12020551185 A1 PH 12020551185A1 PH 12020551185 A PH12020551185 A PH 12020551185A PH 12020551185 A PH12020551185 A PH 12020551185A PH 12020551185 A1 PH12020551185 A1 PH 12020551185A1
Authority
PH
Philippines
Prior art keywords
atopic dermatitis
treatment
nemolizumab
excoriation
moderate
Prior art date
Application number
PH12020551185A
Other languages
English (en)
Inventor
Nabil Kerrouche
Keiko Hirokawa
Ryosuke Mihara
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Publication of PH12020551185A1 publication Critical patent/PH12020551185A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12020551185A 2018-02-09 2020-08-05 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation PH12020551185A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
PH12020551185A1 true PH12020551185A1 (en) 2021-05-17

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551185A PH12020551185A1 (en) 2018-02-09 2020-08-05 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Country Status (23)

Country Link
US (2) US12435147B2 (https=)
EP (2) EP4644424A3 (https=)
JP (3) JP7777921B2 (https=)
CN (1) CN112040976A (https=)
AU (2) AU2019219608B2 (https=)
BR (1) BR112020016144A2 (https=)
CA (1) CA3090062A1 (https=)
CL (1) CL2020002050A1 (https=)
DK (1) DK3749353T3 (https=)
ES (1) ES3049513T3 (https=)
FI (1) FI3749353T3 (https=)
HR (1) HRP20251101T1 (https=)
IL (1) IL276524A (https=)
LT (1) LT3749353T (https=)
MX (1) MX2020008193A (https=)
PH (1) PH12020551185A1 (https=)
PL (1) PL3749353T3 (https=)
PT (1) PT3749353T (https=)
RU (1) RU2758378C1 (https=)
SG (1) SG11202007558YA (https=)
SI (1) SI3749353T1 (https=)
TW (1) TWI856006B (https=)
WO (1) WO2019155427A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025095100A1 (ja) * 2023-11-02 2025-05-08 マルホ株式会社 医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
SG10202112628UA (en) * 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
CL2020002050A1 (es) 2020-12-11
IL276524A (en) 2020-09-30
HRP20251101T1 (hr) 2025-11-21
JP2021512917A (ja) 2021-05-20
TW201941800A (zh) 2019-11-01
BR112020016144A2 (pt) 2020-12-15
WO2019155427A1 (en) 2019-08-15
SG11202007558YA (en) 2020-09-29
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
EP4644424A2 (en) 2025-11-05
TW202448919A (zh) 2024-12-16
RU2758378C1 (ru) 2021-10-28
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
US20200385476A1 (en) 2020-12-10
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
JP2023182632A (ja) 2023-12-26
AU2019219608B2 (en) 2025-10-16
CN112040976A (zh) 2020-12-04
DK3749353T3 (da) 2025-09-01
CA3090062A1 (en) 2019-08-15
SI3749353T1 (sl) 2025-10-30
JP7777921B2 (ja) 2025-12-01
JP2025176134A (ja) 2025-12-03
TWI856006B (zh) 2024-09-21
EP3749353B1 (en) 2025-07-30
US20260008859A1 (en) 2026-01-08
PT3749353T (pt) 2025-10-14
EP4644424A3 (en) 2026-01-14
FI3749353T3 (fi) 2025-09-10

Similar Documents

Publication Publication Date Title
MX2022004259A (es) Inhibidores de mek para el tratamiento de infecciones por hantavirus.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
PH12020551427A1 (en) Epinephrine spray formulations
MX2017014020A (es) Terapia antimicrobiana.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
SA519410324B1 (ar) صياغات رش إيبينيفرين
PH12019550265A1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
EP4640237A3 (en) Macrophage-based therapy for use in the treatment of acute liver injury
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia